Why Ginger Keeps Coming Up

Ginger occupies a strange spot in migraine care. It is one of the most commonly tried self-treatments in the world, it costs almost nothing, it is available in every grocery store, and it gets recommended constantly in migraine communities and on social media. It also has a plausible story behind it: ginger contains gingerols and shogaols, compounds with anti-inflammatory activity and well-documented antiemetic effects, and nausea is one of the most disabling parts of a migraine attack for many people.

What ginger has never had is a proper evidence synthesis. Individual small trials have circulated for years, some of them widely cited, but nobody had pooled them, assessed their risk of bias systematically, and rated how much confidence the results actually deserve.

A new systematic review and meta-analysis in BMJ Evidence-Based Medicine has now done exactly that. The research team from Bond University's Institute for Evidence-Based Healthcare searched six databases, applied the Cochrane Risk of Bias 2 tool, and graded every outcome using GRADE methodology. The conclusion is more cautious than most people expect.

How the Review Worked

The team searched PubMed, Embase, CINAHL, PsycINFO, Epistemonikos and Cochrane CENTRAL from inception through March 2025, then ran an updated search in April 2026. They also did backwards and forwards citation searching on every included study, which catches trials that database searches miss. The protocol was registered on PROSPERO in advance, so the outcomes were specified before the results were known.

They included only randomized controlled trials comparing ginger, either on its own or added to something else, against placebo or an active drug such as sumatriptan, amitriptyline, or valproic acid. Two authors independently screened and extracted data. Outcomes included headache severity, proportion of patients pain free or with meaningful pain relief, attack frequency and duration, and migraine-associated symptoms.

Ginger for an Attack in Progress

Three comparisons were examined for acute treatment. All of them rest on very little data.

The only comparison with a usable pooled estimate was ginger plus ketoprofen versus placebo plus ketoprofen. Headache severity at two hours favored the ginger arm, with a mean difference of 1.27 points lower (95% CI 1.46 to 1.08 lower). That confidence interval does not cross zero, which would normally be described as a positive result. But it rests on a single trial with 60 participants, and the review rated it low certainty. The authors framed it as ginger possibly having little to no meaningful difference, because a single small trial is not enough to support a recommendation.

The other two acute comparisons were weaker still. Ginger combined with feverfew versus placebo, and ginger alone versus sumatriptan, both produced very uncertain results for pain relief, pain freedom, and headache severity at two hours. Very uncertain in GRADE terms means the estimates are close to uninformative.

Ginger as a Preventive

The preventive data were slightly more encouraging.

When ginger was added on top of an active preventive drug and compared against that same drug alone (with or without placebo), pooled headache pain severity at three months was meaningfully lower: a mean difference of 3.18 points (95% CI -3.94 to -2.42), drawn from two studies with 183 participants. The review describes this as potentially an important reduction, while again rating it low certainty.

The rest of the preventive evidence did not hold together. Ginger combined with other herbs versus valproic acid and amitriptyline produced very uncertain results for headache frequency, duration, and severity at three months.

The pattern is consistent. Every comparison that produced a number rested on one or two small trials, and every comparison that pooled more heterogeneous evidence dissolved into uncertainty. This is what an under-researched intervention looks like under close examination.

What Low Certainty Really Means

This applies to far more than ginger.

Low certainty does not mean the treatment does not work. It also does not mean the treatment works and we are just being cautious. It means that our confidence in the estimate is limited, and that further research is likely to change the estimate, possibly substantially. Very low certainty means the estimate should be treated as barely informative.

There is also a comparator problem specific to this review. Several trials used valproic acid and amitriptyline, and one used a ginger-plus-herbs combination rather than ginger alone. Those are not the drugs most people with migraine in the US or Europe are taking in 2026, and combination herbal products make it impossible to know what the ginger itself contributed. That is what GRADE calls indirectness, and it is one of the reasons certainty was downgraded.

So Should You Try It?

"The evidence is too uncertain to say it works" is not the same as "do not bother." It means keeping your expectations modest and deciding on grounds other than proven efficacy.

Ginger's safety profile is one of the reasons it remains a reasonable thing to experiment with. It is generally well tolerated. The most common side effects are heartburn, mild gastrointestinal upset, and an unpleasant aftertaste. It is inexpensive, and there is no evidence it interferes with standard migraine treatments.

The most defensible use case, based on what we know, is ginger as an add-on rather than a replacement. Nobody should be substituting ginger for a triptan, a gepant, a ditan, or a CGRP monoclonal antibody on the strength of this evidence. If you want to try it alongside your existing treatment, track it properly: log your attacks for a month before you start and for two to three months after, and look at frequency and severity rather than relying on your memory of how the last few attacks went. Migraine's natural variability is large enough that informal impressions are unreliable.

If nausea is the worst part of your attacks, ginger's antiemetic evidence is separate from its migraine evidence and considerably stronger. That is probably the most realistic benefit here.

Key Takeaways

The review's wider value is showing how a treatment can be recommended for decades, tried by millions of people, and supported by a handful of repeatedly cited studies, without anyone checking whether the underlying evidence holds up. When someone finally checks, the answer is often "we do not know yet."

That is worth keeping in mind with any migraine treatment: ask how big the trials were, what they compared it against, and whether anyone has replicated the result. Ginger needs an adequately powered trial. Until it gets one, the enthusiasm around it is a hypothesis, not a finding.